Progression of subclinical atherosclerosis in subjects with rheumatoid arthritis and the metabolic syndrome

Atherosclerosis
Benjamin BurggraafManuel Castro Cabezas

Abstract

Rheumatoid arthritis (RA) has been associated with an increased risk of atherosclerosis. We aimed to evaluate the progression of carotid intima media thickness (cIMT) in RA patients subject to a cardiovascular treat-to-target intervention. In addition, the presence of the metabolic syndrome (MetS) on cIMT outcomes was evaluated. We performed a cohort analysis of FRANCIS, in which RA patients ≤70 years without CVD or diabetes mellitus were randomized for either a treat-to-target intervention or usual care concerning CVD risk factors. MetS was scored at baseline. Three-year data was available in 212 well-controlled RA patients. The treat-to-target intervention resulted in a lower cIMT progression over three years compared to the usual care. However, there was no difference in cIMT at three years between groups. MetS was present in 40.1% of RA patients. Baseline cIMT was significantly higher in RA patients with MetS compared to those without (0.619 (0.112) versus 0.557 (0.104) mm; p < 0.001). After three years, cIMT progression was comparable (0.043 (0.071) versus 0.043 (0.072) mm; p = 0.96). In RA patients with MetS, the presence of plaques increased over three years from 12.9% to 23.5% (p = 0.01). The type of intervention had no...Continue Reading

References

Dec 4, 2002·JAMA : the Journal of the American Medical Association·Hanna-Maaria LakkaJukka T Salonen
Oct 1, 2003·Circulation·Muredach P Reilly, Daniel J Rader
Mar 8, 2005·Arthritis and Rheumatism·Hilal Maradit-KremersSherine E Gabriel
Oct 14, 2008·Atherosclerosis·Kalle SipiläMika Kähönen
Nov 28, 2008·Arthritis and Rheumatism·J Antonio Aviña-ZubietaDiane Lacaille
Sep 25, 2010·Journal of the American College of Cardiology·Salvatore MottilloMark J Eisenberg
Oct 5, 2010·Seminars in Arthritis and Rheumatism·Alper M van SijlMichael T Nurmohamed
Oct 4, 2011·Arthritis and Rheumatism·Jon T GilesJoan M Bathon
May 3, 2012·Stroke; a Journal of Cerebral Circulation·Marit HerderEllisiv B Mathiesen
Jun 29, 2012·Cardiovascular Diabetology·Marit HerderEllisiv B Mathiesen
Jan 31, 2014·Journal of Atherosclerosis and Thrombosis·Jin-Man JungMoon Ho Park
May 23, 2014·Annals of the Rheumatic Diseases·Inmaculada Del RincónAgustín Escalante
Feb 27, 2015·Thrombosis and Haemostasis·Pasquale AmbrosinoMatteo Nicola Dario Di Minno
Aug 19, 2015·Nature Reviews. Rheumatology·Michael T NurmohamedGeorge D Kitas
Feb 18, 2016·Korean journal of family medicine·Sang-Hyun LeeSoo Hyun Jang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.